Overdiagnosis as an extreme form of length-time bias Breast cancer screening as example Juan Gérvas, MD, PhD, Equipo CESCA, Madrid, Spain

Slides:



Advertisements
Similar presentations
Breast Cancer Early Detection is Your Best Protection
Advertisements

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
HOW STANDING ORDERS HELPED US IMPROVE CANCER SCREENING: REPORT FROM A NEW PPRNet MEMBER JULIO A SAVINON, MD RIO GRANDE MEDICINE INC. HARLINGEN, TX.
SCREENING FOR DISEASE Nigel Paneth. THREE KEY MEASURES OF VALIDITY 1.SENSITIVITY 2.SPECIFICITY 3.PREDICTIVE VALUE.
1 EPI-820 Evidence-Based Medicine LECTURE 5: SCREENING Mat Reeves BVSc, PhD.
The origin of metastatic disease: clues from genomics 7/13/2011.
Meta-Analysis of PSA Growth Lurdes Y.T. Inoue, Ph.D. Ruth Etzioni, Ph.D. Elizabeth Slate, Ph.D. Christopher Morrel, Ph.D.
Cancer Clinical Trials:
Screening revision! By Ilona Blee. What are some UK Screening programmes?  Antenatal & newborn screening  Newborn Blood Spot  Newborn Hearing Screening.
Principles of Epidemiology Lecture 12 Dona Schneider, PhD, MPH, FACE
Health Promotion and Disease Prevention-focus on Cancer Edward Anselm, MD Assistant Professor of Medicine Icahn School of Medicine at Mount Sinai Medical.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Screening PHIL THIRKELL. What is screening?  A process of identifying apparently healthy people who may be at risk of a disease or condition  Identify.
© Open University Press, 2004 Overview Prevention and screening Psychological predictors of screening The ethics and usefulness of screening? Psychological.
Breast Cancer Screening Beyond 70 Years Old Henry Kwok Breast Imaging Fellow BreastScreen Aotearoa Counties Manukau.
Stage-specific survival of screen-detected versus clinically diagnosed colorectal cancer - evidence from the FOBT screening trials- Iris Lansdorp-Vogelaar.
Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.
The Nature of Disease.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Clare Rogers Consultant Breast Surgeon Doncaster and Bassetlaw Hospitals.
Prostate Screening in 2009: New Findings and New Questions Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer.
Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 21, 2010.
EPIB-591 Screening Jean-François Boivin 29 September
Diagnostic Cases. Goals & Objectives Highlight Bayesian and Boolean processes used in classic diagnosis Demonstrate use/misuse of tests for screening.
1 MAMMOGRAPHY RADIOGRAPHIC IMAGING OF THE BREAST Part 2 -Statistics A mammogram can find breast cancer when it is very small -- 2 to 3 years before you.
EDRN Approaches to Biomarker Validation DMCC Statisticians Fred Hutchinson Cancer Research Center Margaret Pepe Ziding Feng, Mark Thornquist, Yingye Zheng,
 Cancer is a group of more than 100 diseases that develop over time › Involve the uncontrolled division of the body’s cells  Cancer is the 2 nd leading.
Reliability of Screening Tests RELIABILITY: The extent to which the screening test will produce the same or very similar results each time it is administered.
Vanderbilt Sports Medicine How to practice and teach EBM Chapter 3 May 3, 2006.
“The African American Prostate Cancer Crisis in Numbers”
1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
In The Name of God BREAST IMAGING N. Ahmadinejad Medical Imaging Center TUMS.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
Screening Puja Myles
Cost-effectiveness of Screening Tests Mark Hlatky, MD Stanford University.
Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Screening of diseases Dr Zhian S Ramzi Screening 1 Dr. Zhian S Ramzi.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 23, 2008.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Screening.  “...the identification of unrecognized disease or defect by the application of tests, examinations or other procedures...”  “...sort out.
Senior Statistician Per-Henrik Zahl, MA MD PhD
Clinical Epidemiology and Evidence-based Medicine Unit FKUI – RSCM
BC Cancer Agency CARE & RESEARCH Breast Cancer Mortality After Screening Mammography in British Columbia Women Andrew J. Coldman, Ph.D. Norm Phillips,
Breast cancer facts Daniela Cazares. Fact #1 In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
The Elliott Breast Center * Baton Rouge, LA *
BREAST SELF- AWARENESS FOR OUR COMMUNITY Updated 3/2015.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Date of download: 7/6/2016 From: Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies: Model Estimates.
Tumor markers 1111.
Cancer Screening Guidelines
Underwriting Breast Cancer
CELL DIVISION GOING WRONG: Cancer
Breast, prostate, and thyroid cancer screening tests and overdiagnosis
From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 YearsA Comparative Modeling Study of Risk Ann Intern.
Cancer screening PROF .MAZIN AL-HAWAZ.
Cancer Staging.
Dr. Hannah Jordan Lecturer in Public Health ScHARR
Volume 4, Issue 1, Pages 4-6 (July 2003)
Lung Cancer: A Wily Genetic Opponent
Evidence Based Diagnosis
Presentation transcript:

Overdiagnosis as an extreme form of length-time bias Breast cancer screening as example Juan Gérvas, MD, PhD, Equipo CESCA, Madrid,

 Overdiagnosis is an extreme form of length-time bias and occurs when screening detects indolent tumors that meet diagnostic criteria for cancer but would not otherwise have come to clinical attention during the lifetime of the individual. Reference: Failure of Researchers, Reviewers, Editors, and the Media to Understand Flaws in Cancer Screening Studies.Berry DA. Cancer. 2014;(Article first published online: 12 JUN 2014):1–8. doi: /cncr  Overdiagnosis artificially inflates the case survival rate.  Overdiagnosed patients obtain no benefit while being subjected to all of the harms of treatment.

ABCD A = Tumor onset B = Beginning of the period in which breast cancer can be diagnosed with screening mammography C = Start of the clinical phase (signs-symptoms) of breast cancer D = Death because breast cancer, o for any cause BC = Latency (sojourn), period for early detection = Critical point of irreversibility S s SB = Lead time bias. BC = Length time bias when BC is longer than usual, or even close or equal to "n" (being "n" the number of years of health expectancy at the time of diagnosis). Overdiagnosis "stricto sensu" means that BC is equal to "n".

A = Tumor onset B = Beginning of the period in which breast cancer can be diagnosed with screening mammography C = Start of the clinical phase (signs-symptoms) of breast cancer D = Death because breast cancer, o for any cause BC = Latency (sojourn), period for early detection = Critical point of irreversibility s SB = Lead time bias. BC = Length time bias when BC is longer than usual, or even close or equal to "n" (being "n" the number of years of health expectancy at the time of diagnosis). Overdiagnosis "stricto sensu" means that BC is equal to "n". ABD S C In some cases C could be before B (and the latency period becomes negative)

1. Lead-time bias. The increment in survival among screen-detected cases that equals the difference in time of detection and when the cancer would have been detected otherwise. Labeling individuals earlier as having cancer means they will live longer after having been so labeled. 2. Length bias. The increment in survival among screen-detected cases because of the over selection of slowly growing cancers. Cancers that are slowly growing have a longer period between the time a tumor can be detected on a mammogram and when it will become evident from symptoms. 3. Sojourn (latency) period. The time a tumor can be detected on a mammogram until when it will become evident from signs-symptoms. The distribution of sojourn time in breast cancer is unknown. Sojourn time varies, depending on factors such as age and breast density. Typical estimates range from 4 years to 7 years. 4. Critical point of irreversibility. Starting period of invasive cancer (metastasis or development of a clon which will "kill" the female without treatment). DEFINITIONS

 Overdiagnosis is an error of prognosis.  We do not know why overdiagnosis is so common and, worse, we cannot separate tumors that are overdiagnosis (we cannot at the time of diagnosis identify "overdiagnosis tumors“)  In the future, genetic intratumoral heterogeneity (the presence of multiple clones, intratumoral genetic chaos) might help CONCLUSIONS (I)  Overdiagnosis is not an error of diagnosis (overdiagnosis is not a false positive) References: Bewildering genetic intratumor heterogeneity: Evolution through space and time. Available in: Cancer intra-heterogeneity. Can the degree of genetic chaos accurately predict of tumour recurrence? Probably. Available in: Overdiagnosis. Tracking the clonal origin of lethal prostate cancer. Available in:

 In the future, genetic intratumoral heterogeneity (the presence of multiple clones, intratumoral genetic chaos) might help. At least in mice, mechanical properties of tumors differs substantially from normal cells and tissues so macroscopic stiffness of breast tumors predicts metastasis. CONCLUSIONS (II)  We don’t know why overdiagnosis is so common and, worse, we cannot separate tumors that are overdiagnosis (we cannot at the time of diagnosis identify "overdiagnosis tumors"). References: Macroscopic stiffness of breast tumors predicts metastasis. Available in: